Cellumed Co.,Ltd.

KOSDAQ:A049180 Stock Report

Market Cap: ₩125.4b

CellumedLtd Past Earnings Performance

Past criteria checks 0/6

CellumedLtd's earnings have been declining at an average annual rate of -4.3%, while the Medical Equipment industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 21.4% per year.

Key information

-4.3%

Earnings growth rate

20.2%

EPS growth rate

Medical Equipment Industry Growth22.7%
Revenue growth rate21.4%
Return on equity-95.4%
Net Margin-25.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Benign Growth For Cellumed Co.,Ltd. (KOSDAQ:049180) Underpins Stock's 35% Plummet

Nov 01
Benign Growth For Cellumed Co.,Ltd. (KOSDAQ:049180) Underpins Stock's 35% Plummet

Cellumed Co.,Ltd.'s (KOSDAQ:049180) Low P/S No Reason For Excitement

Aug 27
Cellumed Co.,Ltd.'s (KOSDAQ:049180) Low P/S No Reason For Excitement

CellumedLtd (KOSDAQ:049180) Has Debt But No Earnings; Should You Worry?

Jun 04
CellumedLtd (KOSDAQ:049180) Has Debt But No Earnings; Should You Worry?

Revenue & Expenses Breakdown

How CellumedLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A049180 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24119,645-30,91624,671932
30 Jun 24111,867-30,23825,002989
31 Mar 24102,157-33,35126,4001,423
31 Dec 2395,553-37,28026,2011,506
30 Sep 2395,474-20,08116,9081,681
30 Jun 23101,425-19,70016,7021,673
31 Mar 23112,943-13,16715,0311,326
31 Dec 22122,085-5,36815,0481,523
30 Sep 22126,0157,46012,0991,542
30 Jun 22121,36111,3398,7321,469
31 Mar 22109,83210,2578,1111,351
31 Dec 2199,9188,0107,0871,170
30 Sep 2184,5642,9317,968599
30 Jun 2182,01012410,973615
31 Mar 2177,548-3810,2161,216
31 Dec 2073,188-1,07810,576783
30 Sep 2066,694-31,9519,716985
30 Jun 2045,315-34,3979,160893
31 Mar 2029,904-35,7629,219470
31 Dec 1917,921-36,4228,980642
30 Sep 1910,983-17,8819,454492
30 Jun 1910,156-15,4288,011342
31 Mar 199,311-7,01210,203193
31 Dec 189,915-7,89010,152205
30 Sep 1813,7829697,697716
30 Jun 1815,763-7839,571725
31 Mar 1818,279-8,5416,987553
31 Dec 1719,904-6,3026,312655
30 Sep 1716,388-11,05013,992650
30 Jun 1714,696-10,62413,479268
31 Mar 1712,076-34,74313,887729
31 Dec 169,814-36,58814,081564
30 Sep 1612,815-35,6169,353153
30 Jun 1612,563-38,04610,486316
31 Mar 1615,415-13,63010,798153
31 Dec 1517,731-11,34510,453153
30 Sep 1514,764-19,49315,4645
30 Jun 1517,681-15,94014,627187
31 Mar 1520,532-13,72414,7355
31 Dec 1420,735-14,91315,7535
30 Sep 1428,948-2,19310,3630
30 Jun 1429,324-1,98310,2700
31 Mar 1427,159-3,35510,6960

Quality Earnings: A049180 is currently unprofitable.

Growing Profit Margin: A049180 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A049180 is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare A049180's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A049180 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-16.5%).

Return on Equity

High ROE: A049180 has a negative Return on Equity (-95.42%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 19:13
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellumed Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution